BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Editorial

  Watch Out Novo, Lilly Is Closing the Gap in the Weight-Loss Drug Race

  This week, Q2 earnings from Novo Nordisk and Eli Lilly revealed that the competition between the pharma giants’ weight-loss drugs Wegovy and Zepbound is getting closer.

  August 9, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  Approvals

  Citius Scores FDA Approval in Cutaneous T Cell Lymphoma

  Citius Pharmaceuticals’ Lymphir is a reformulated version of denileukin diftitox—an FDA-approved cancer therapy—and the only treatment for cutaneous T cell lymphoma that targets the IL-2 receptor located on malignant T cells and Tregs.

  August 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Legal

  Federal Judge Tosses Chamber of Commerce Challenge to IRA’s Drug Price Negotiation Program

  In the latest setback for the pharma industry and its allies, the United States District Court for the Southern District of Ohio dismissed a U.S. Chamber of Commerce lawsuit on the grounds of improper venue.

  August 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Psychedelics

  FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy After Negative Adcomm

  Clinical trial concerns and a negative advisory committee vote ultimately sunk the treatment.

  August 9, 2024

   · 

  6 min read

   · 

  Kenny Walter
• 

  Earnings

  Gilead Beats Q2 Wall Street Estimates on Strong HIV, Cancer, Liver Disease Sales

  Gilead Sciences’ liver disease portfolio delivered surprisingly robust performance in the second quarter, jumping 17% as the company awaits next week’s potential FDA approval of seladelpar in primary biliary cholangitis.

  August 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  J&J’s Stelara More Expensive Under Medicare Part D Than Part B: OIG

  With Medicare expenditures on Stelara increasing nearly tenfold, a new report from the HHS Office of Inspector General has found major differences in drug payment amounts under Part B versus Part D.

  August 9, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Layoffs

  AN2 Therapeutics Laying Off Half Its Workforce

  AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.

  August 9, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Mergers & acquisitions

  Merck Puts Up Potential $1.3B to Acquire Curon’s B Cell Depletion Therapy

  Merck is paying $700 million upfront to buy Curon Biopharmaceutical’s bispecific antibody which depletes B cells and is being investigated for non-Hodgkin’s lymphoma and B cell acute lymphocytic leukemia.

  August 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

  August 9, 2024

   · 

  9 min read
• Press Releases

  CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

  August 9, 2024

   · 

  13 min read